Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung Cancer

Yoshimasu, Tatsuya; Oura, Shoji; Ohta, Fuminori; Hirai, Yoshimitsu; Naito, Koma; Nakamura, Rie; Nishiguchi, H; Hashimoto, Sayoko; Kawago, Mitsumasa; Okamura, Yoshitaka

doi:10.1097/jto.0b013e318221f71a

Cited by 15 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study reported by Lee et al9 found no obvious relationship between presence of EGFR mutation and the effectiveness of first-line chemotherapy. However, a recent Japanese study indicated that patients with the EGFR mutation were less sensitive to docetaxel than those with wild-type EGFR 10. Our study showed that the response rate and disease control rate of the first-line chemotherapy platinum containing regimens were both higher in patients with the EGFR mutation than in patients with EGFR wild-type in advanced NSCLC.…”

Section: Discussionmentioning

confidence: 42%

“…Several Phase III clinical trials also indicated that NSCLC patients with mutated EGFR had better clinical outcomes from treatment with erlotinib or gefitinib than from normal chemotherapy 5–7. At present, EGFR is the primary predictor of a curative effect of EGFR TKIs, and the relevant research8–10 has shown that the mutation status of EGFR is probably the main determinant of response to first-line chemotherapy and the prognosis in patients with advanced NSCLC.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Fang¹,

Wang²,

Guo³

et al. 2014

OTT

View full text Add to dashboard Cite

BackgroundThe purpose of this research was to investigate the relationship between epidermal growth factor receptor (EGFR) mutations and the response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).MethodsA total of 266 patients with stage IIIB or IV NSCLC who received platinum-based doublet therapies as first-line chemotherapy were investigated retrospectively, and their clinical data were assessed according to EGFR mutation.ResultsEGFR mutations were identified in 45.5% of patients. There was no significant difference in response rate between EGFR mutation carriers and EGFR wild-type carriers (P=0.484). Among the patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) wild-type, however, those with EGFR mutations responded better to treatment than EGFR wild-type patients (46.2% versus 20.8%, P=0.043). The disease control rate associated with pemetrexed-based treatments was higher than for vinorelbine-based therapies in EGFR mutation patients (P=0.001). EGFR mutation was found in patients with longer progression-free survival and median survival time, and improved 1-year and 2-year overall survival when compared with EGFR wild-type patients (6.1 versus 5.0 months, P=0.004; 18.9 versus 13.8 months, P=0.001; 81.0% versus 63.4%, P=0.002; and 33.9% versus 22.8% P=0.044, respectively). Patients with the EGFR exon 19 mutation had longer progression-free survival than those with EGFR exon 21 mutation (P=0.007). Multivariate analysis showed that the response to first-line chemotherapy and the presence of EGFR mutations were independent prognostic factors in patients with advanced NSCLC.ConclusionOur data showed that the presence of EGFR mutations meant longer survival times for patients with advanced NSCLC who received platinum-based doublet first-line chemotherapy, especially in those with the exon 19 deletion mutation. Among KRAS wild-type patients, those with EGFR mutation responded better to first-line chemotherapy than EGFR wild-type patients.

show abstract

Section: Discussionmentioning

confidence: 42%

Section: Introductionmentioning

confidence: 99%

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Fang¹,

Wang²,

Guo³

et al. 2014

OTT

View full text Add to dashboard Cite

show abstract

“…In contrast, a chemosensitivity test performed by Yoshimasu et al 62 demonstrated that the sensitivity to docetaxel was lower in lung cancers with EGFR mutations compared with in tumors with wild-type EGFR .…”

Section: Egfr Mutations As a Predictive Marker For Response mentioning

confidence: 89%

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

Fang¹,

Wang²

2014

DDDT

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) has entered the age of individual treatment, and increasing point mutations of specific oncogenes and rearrangement of some chromosomes are biomarkers used to predict the therapeutic effect of targeted therapy. At present, there is a consensus among clinicians that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown favorable efficacy in NSCLC patients with EGFR mutation, and some relevant research has suggested that the presence of EGFR mutations is a favorable prognostic marker. However, the association of EGFR mutation status with the responsiveness to conventional chemotherapy agents and survival in NSCLC patients is still unclear. This review provides an overview of and assesses the role of EGFR as a prognostic marker for postoperative patients and as a predictive marker for response to cytotoxic chemotherapy. In addition, we review the comparison of response to chemotherapy between EGFR mutations in exon 19 and in exon 21 and the predictive role of p.T790M mutation.

show abstract

“…The INTEREST trial has previously reported that response rate to docetaxel was higher in patients with EGFR mutations, compared with wild-type EGFR cases [12]. In contrast, the recent results of a chemosensitivity test using patient tissue has reported that lung cancers with EGFR mutations were less sensitive to docetaxel than wild-type EGFR tumors [13].…”

Section: Introductionmentioning

confidence: 94%

EGFR mutations as a predictive marker of cytotoxic chemotherapy

Park¹,

Lee²,

Keam³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

Epidermal Growth Factor Receptor Mutations Are Associated with Docetaxel Sensitivity in Lung Cancer

Abstract: The histoculture drug response assay indicated that lung cancers with EGFR mutations were less sensitive to DOC than EGFR wild-type tumors.

Cited by 15 publications

References 19 publications

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

Correlation between EGFR mutation status and response to first-line platinum-based chemotherapy in patients with advanced non-small cell lung cancer

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer

EGFR mutations as a predictive marker of cytotoxic chemotherapy

Contact Info

Product

Resources

About